Daptomycin-induced eosinophilic pneumonia: Are there any risk factors?

Fiche publication


Date publication

janvier 2021

Journal

Infectious diseases now

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BONNIAUD Philippe, Dr BELTRAMO Guillaume


Tous les auteurs :
Ahouansou N, Georges M, Beltramo G, Aswad N, Hassani Y, Bonniaud P

Résumé

Daptomycin is a widely used antibiotic. Rhabdomyolysis related to daptomycin is one of the adverse effects of treatment, justifying the need for regular monitoring of muscle enzymes throughout treatment. Daptomycin may also lead to eosinophilic pneumonia. However, risk factors for this adverse reaction have not been identified and do not permit targeting of at-risk populations who could benefit from appropriate monitoring.

Mots clés

Daptomycin, Pulmonary eosinophilia, Risk factor

Référence

Infect Dis Now. 2021 Jan 9;: